| The role of female hormonal factors in the development of rheumatoid arthritis D Alpízar-Rodríguez, N Pluchino, G Canny, C Gabay, A Finckh Rheumatology 56 (8), 1254-1263, 2017 | 195 | 2017 |
| The role of leptin in innate and adaptive immune responses E Bernotiene, G Palmer, C Gabay Arthritis research & therapy 8, 1-10, 2006 | 194 | 2006 |
| Regulation and function of interleukin‐36 cytokines EY Bassoy, JE Towne, C Gabay Immunological reviews 281 (1), 169-178, 2018 | 192 | 2018 |
| Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. A Desgeorges, CEM Gabay, P Silacci, D Novick, P Roux-Lombard, ... The Journal of rheumatology 24 (8), 1510-1516, 1997 | 181 | 1997 |
| Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double‐blind, placebo‐controlled clinical trial at a single center C Gabay, C Medinger‐Sadowski, D Gascon, F Kolo, A Finckh Arthritis & Rheumatism 63 (11), 3383-3391, 2011 | 176 | 2011 |
| Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions JS Smolen, MM Schoels, N Nishimoto, FC Breedveld, GR Burmester, ... Annals of the rheumatic diseases 72 (4), 482-492, 2013 | 160 | 2013 |
| Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis C Gabay, IB McInnes, A Kavanaugh, K Tuckwell, M Klearman, J Pulley, ... Annals of the rheumatic diseases 75 (10), 1806-1812, 2016 | 157 | 2016 |
| Tolerance and effectiveness of anti–tumor necrosis factor α therapies in elderly patients with rheumatoid arthritis: A population‐based cohort study S Genevay, A Finckh, A Ciurea, AM Chamot, D Kyburz, C Gabay, ... Arthritis Care & Research 57 (4), 679-685, 2007 | 157 | 2007 |
| Physiologic role of interleukin-1 receptor antagonist WP Arend, C Gabay Arthritis Research & Therapy 2, 1-4, 2000 | 155 | 2000 |
| Impact of synthetic and biologic disease‐modifying antirheumatic drugs on antibody responses to the AS03‐adjuvanted pandemic influenza vaccine: a prospective, open‐label … C Gabay, M Bel, C Combescure, C Ribi, S Meier, K Posfay‐Barbe, ... Arthritis & Rheumatism 63 (6), 1486-1496, 2011 | 145 | 2011 |
